Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease
ACS Chemical Biology · 2025
DOI: 10.1021/acschembio.4c00602 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, 2025. Verfasst von Senthilkumar Deivasigamani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Esya Ltd., 84 Wood Lane, London W12 0BZ, U.K. Hauptthemen laut MEDLINE: Alzheimer Disease, Lysosomes, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Alzheimer's Drug Discovery Foundation, Innovate UK, Michael J. Fox Foundation for Parkinson's Research.
Themen: Demenz
Abstract (Originalsprache)
Lysosomal storage disorders (LSDs) and adult neurodegenerative disorders like Alzheimer's disease (AD) share various clinical and pathophysiological features. LSDs are characterized by impaired lysosomal activity caused by mutations in key proteins and enzymes. While lysosomal dysfunction is also linked to AD pathogenesis, its precise role in disease onset or progression remains unclear. Lysosomal ionic homeostasis is recognized as a key feature of many LSDs, but it has not been clinically linked with AD pathology. Thus, investigating whether this regulation is disrupted in AD is important, as it could lead to new therapeutic targets and biomarkers for this multifactorial disease. Here, using two-ion mapping (2-IM) technology, we quantitatively profiled lysosomal pH and Ca2+ in blood-derived monocytes from AD patients and age-matched controls and correlated lysosome ionicity with age and key markers of AD pathology, namely, amyloid deposits, tauopathy, neurodegeneration, and inflammation. Together, the data show that the ionic milieu of lysosomes is dysregulated in monocytes of AD patients and correlates with key plasma biomarkers of AD. Using a machine learning model based on the above parameters, we describe a proof-of-concept combinatorial biomarker platform that accurately distinguishes between patients with AD and control participants with an area under the curve of >96%. Our study introduces a convenient, noninvasive platform with the potential to diagnose Alzheimer's disease based on fluid, cellular, and molecular biomarkers. Further, these findings highlight the potential for investigating therapeutic mechanisms capable of restoring lysosome ionic homeostasis to ameliorate AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Esya Ltd., 84 Wood Lane, London W12 0BZ, U.K.
- Neuroscience Department, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
- Department of Chemistry, The University of Chicago, Chicago, Illinois 60637, United States.
- Neuroscience Institute, The University of Chicago, Chicago, Illinois 60637, United States.
- Institute for Biophysical Dynamics, The University of Chicago, Chicago, Illinois 60637, United States.
ORCID-Profile: Hernando M Vergara, Jason Uslaner, Yamuna Krishnan, Souvik Modi
Förderung
- Alzheimer's Drug Discovery Foundation
- Innovate UK
- Michael J. Fox Foundation for Parkinson's Research
Zitieren
APA
Deivasigamani, S., Thekkan, S., Vergara, H. M., Conolly, O., Cosden, M., Phan, T., Smith, S., Marcus, J., Uslaner, J., Venkat, D., Drolet, R. E., Krishnan, Y., & Modi, S. (2025). Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease. ACS Chemical Biology. https://doi.org/10.1021/acschembio.4c00602
Vancouver
Deivasigamani S, Thekkan S, Vergara HM, Conolly O, Cosden M, Phan T, et al. Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease. ACS Chemical Biology. 2025. doi:10.1021/acschembio.4c00602
BibTeX
@article{Deivasigamani2025,
author = {Deivasigamani, Senthilkumar and Thekkan, Shareefa and Vergara, Hernando M and Conolly, Owen and Cosden, Mali and Phan, Thienlong and Smith, Sean and Marcus, Jacob and Uslaner, Jason and Venkat, Dhivya and Drolet, Robert E and Krishnan, Yamuna and Modi, Souvik},
title = {Multimodal Blood-Based Biomarker Panel Reveals Altered Lysosomal Ionic Content in Alzheimer’s Disease},
journal = {ACS Chemical Biology},
year = {2025},
doi = {10.1021/acschembio.4c00602}
}
EUVIMED